266 related articles for article (PubMed ID: 10709099)
1. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening SA
Int J Cancer; 2000 Mar; 85(6):801-4. PubMed ID: 10709099
[TBL] [Abstract][Full Text] [Related]
2. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.
Xing Y; Shepherd N; Lan J; Li W; Rane S; Gupta SK; Zhang S; Dong J; Yu Q
Brain Behav Immun; 2017 Oct; 65():161-172. PubMed ID: 28487203
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
4. Metalloproteinases and Their Inhibitors in Patients with Inguinal Hernia.
Isik A; Gursul C; Peker K; Aydın M; Fırat D; Yılmaz İ
World J Surg; 2017 May; 41(5):1259-1266. PubMed ID: 28050662
[TBL] [Abstract][Full Text] [Related]
5. The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide.
Hemmerlein B; Johanns U; Halbfass J; Böttcher T; Heuser M; Radzun HJ; Thelen P
Int J Oncol; 2004 May; 24(5):1069-76. PubMed ID: 15067327
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
7. Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.
Negaard HF; Svennevig K; Kolset SO; Iversen N; Lothe IM; Østenstad B; Sandset PM; Iversen PO
Leuk Lymphoma; 2009 Jun; 50(6):998-1004. PubMed ID: 19373600
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
9. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
10. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
11. [Age-related dynamics of the contents of matrix metalloproteinases (MMP-1, -2, -3, -9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -4) in blood plasma of residents of the European part of the Arctic zone of the Russian Federation.].
Kim LB; Russkih GS; Putyatina AN; Tsypysheva OB
Adv Gerontol; 2018; 31(2):223-230. PubMed ID: 30080329
[TBL] [Abstract][Full Text] [Related]
12. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
14. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
16. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.
Tayebjee MH; Lip GY; Blann AD; Macfadyen RJ
Thromb Res; 2005; 115(3):205-10. PubMed ID: 15617743
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human fetal testis and ovary.
Robinson LL; Sznajder NA; Riley SC; Anderson RA
Mol Hum Reprod; 2001 Jul; 7(7):641-8. PubMed ID: 11420387
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical localization of matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in tuberculous pleuritis].
Hoheisel G; Sack U; Hui DS; Lai F; Chan KS; Choi CH; Schauer J; Tannapfel A
Pneumologie; 2004 May; 58(5):305-8. PubMed ID: 15162254
[TBL] [Abstract][Full Text] [Related]
20. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
